Bio Green Med Solution, Inc. (BGMS)
NASDAQ: BGMS · Real-Time Price · USD
0.935
-0.015 (-1.58%)
At close: Mar 9, 2026, 4:00 PM EDT
0.935
-0.000 (-0.04%)
After-hours: Mar 9, 2026, 5:11 PM EDT
Bio Green Med Solution Revenue
Bio Green Med Solution had revenue of $81.00K in the quarter ending September 30, 2025, with 710.00% growth. This brings the company's revenue in the last twelve months to $81.00K, up 9.46% year-over-year. In the year 2024, Bio Green Med Solution had annual revenue of $43.00K, down -89.76%.
Revenue (ttm)
$81.00K
Revenue Growth
+9.46%
P/S Ratio
56.87
Revenue / Employee
$6,750
Employees
12
Market Cap
4.58M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GeoVax Labs | 3.35M |
| Xenetic Biosciences | 2.86M |
| Cyclerion Therapeutics | 2.86M |
| BioRestorative Therapies | 383.40K |
| VivoSim Labs | 142.00K |
| Silo Pharma | 72.10K |
BGMS News
- 4 months ago - Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB - GlobeNewsWire
- 8 months ago - Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday? - Benzinga
- 8 months ago - CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER - GlobeNewsWire
- 8 months ago - CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT - GlobeNewsWire
- 8 months ago - Cyclacel Pharmaceuticals Announces Stock Split - GlobeNewsWire
- 9 months ago - Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock - GlobeNewsWire